...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
【24h】

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda

机译：卢旺达艾滋病毒杂化患者利福平抗性结核病死亡率预测

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tuberculosis (TB), including multidrug-resistant (MDR; i.e., resistant to at least rifampicin and isoniazid)/rifampicin-resistant (MDR/RR) TB, is the most important opportunistic infection among people living with HIV (PLHIV). In 2005, Rwanda launched the programmatic management of MDR/RR-TB. The shorter MDR/RR-TB treatment regimen (STR) has been implemented since 2014. We analyzed predictors of MDR/RR-TB mortality, including the effect of using the STR overall and among PLHIV. This retrospective study included data from patients diagnosed with RR-TB in Rwanda between July 2005 and December 2018. Multivariable logistic regression was used to assess predictors of mortality. Of 898 registered MDR/RR-TB patients, 861 (95.9%) were included in this analysis, of whom 360 (41.8%) were HIV coinfected. Overall, 86 (10%) patients died during MDR/RR-TB treatment. Mortality was higher among HIV-coinfected compared with HIV-negative TB patients (13.3% versus 7.6%). Among HIV-coinfected patients, patients aged >= 55 years (adjusted odds ratio = 5.89) and those with CD4 count <= 100 cells/mm(3) (adjusted odds ratio = 3.77) had a higher likelihood of dying. Using either the standardized longer MDR/RR-TB treatment regimen or the STR was not correlated with mortality overall or among PLHIV. The STR was as effective as the long MDR/RR-TB regimen. In conclusion, older age and advanced HIV disease were strong predictors of MDR/RR-TB mortality. Therefore, special care for elderly and HIV-coinfected patients with <= 100 CD4 cells/mL might further reduce MDR/RR-TB mortality.
机译：结核病（TB），包括耐多药（MDR；即至少对利福平和异烟肼耐药）/耐利福平（MDR/RR）结核病，是HIV感染者（PLHIV）中最重要的机会性感染。2005年，卢旺达启动了耐多药/抗药性结核病的方案管理。自2014年以来，已实施了较短的耐多药/耐多药结核病治疗方案（STR）。我们分析了耐多药/耐多药结核病死亡率的预测因素，包括使用STR对整体和PLHIV的影响。这项回顾性研究包括2005年7月至2018年12月期间在卢旺达诊断为RR-TB的患者的数据。多变量逻辑回归用于评估死亡率的预测因素。在898名登记的耐多药/耐多药结核病患者中，861人（95.9%）被纳入本分析，其中360人（41.8%）同时感染艾滋病毒。总的来说，86名（10%）患者在耐多药/耐多药结核病治疗期间死亡。与HIV阴性结核患者相比，HIV合并感染者的死亡率更高（13.3%对7.6%）。在HIV合并感染患者中，年龄大于等于55岁（调整后的优势比=5.89）和CD4计数小于等于100个细胞/毫米（3）（调整后的优势比=3.77）的患者死亡的可能性更高。使用标准化的长期耐多药/抗逆转录病毒结核病治疗方案或STR与总体死亡率或PLHIV之间没有相关性。STR与长期MDR/RR-TB方案一样有效。总之，老年人和晚期HIV疾病是耐多药/耐多药结核病死亡率的有力预测因素。因此，对CD4细胞/mL≤100的老年人和HIV合并感染患者的特殊护理可能进一步降低MDR/RR-TB死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号